EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease

Sophia Weiner, Mathias Sauer, Gunnar Brinkmalm, Julius Constantinescu, Radu Constantinescu, Bárbara Fernandes Gomes, Bruno Becker, Bengt Nellgård, Keti Dalla, Douglas Galasko, Henrik Zetterberg, Kaj Blennow und 1 weitere

Alzheimer's & Dementia · 2023

DOI: 10.1002/alz.13042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Sophia Weiner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Nerve Tissue Proteins, tau Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Alzheimer's Association, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Secernin‐1 (SCRN1) is a neuronal protein that co‐localizes with neurofibrillary tangles in Alzheimer's disease (AD), but not with tau inclusions in corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), or Pick's disease. METHODS We measured SCRN1 concentration in cerebrospinal fluid (CSF) using a novel mass spectrometric parallel reaction monitoring method in three clinical cohorts comprising patients with neurochemically characterized AD ( n = 25) and controls ( n = 28), clinically diagnosed Parkinson's disease (PD; n = 38), multiple system atrophy (MSA; n = 31), PSP ( n = 20), CBD ( n = 8), healthy controls ( n = 37), and neuropathology‐confirmed AD ( n = 47). RESULTS CSF SCRN1 was significantly increased in AD ( P < 0.01, fold change = 1.4) compared to controls (receiver operating characteristic area under the curve = 0.78) but not in CBD, PSP, PD, or MSA. CSF SCRN1 positively correlated with CSF total tau ( R = 0.78, P = 1.1 × 10 −13 ), phosphorylated tau 181 ( R = 0.64, P = 3.2 × 10 −8 ), and Braak stage and negatively correlated with Mini‐Mental State Examination score. DISCUSSION CSF SCRN1 is a candidate biomarker of AD, reflecting tau pathology. HIGHLIGHTS We developed a parallel reaction monitoring assay to measure secernin‐1 (SCRN1) in cerebrospinal fluid (CSF). CSF SCRN1 was increased in Alzheimer's disease compared to healthy controls. CSF SCRN1 remained unchanged in Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration compared to controls. CSF SCRN1 correlated strongly with CSF phosphorylated tau and total tau. CSF SCRN1 increased across Braak stages and negatively correlated with Mini‐Mental State Examination score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNerve Tissue Proteinstau ProteinsHumansBiomarkersCorticobasal DegenerationMultiple System AtrophyParkinson DiseaseSupranuclear Palsy, Progressive

Stichwörter der Autor:innen

Alzheimer's diseaseParkinsonian syndromesbiomarkerscerebrospinal fluidmass spectrometrysecernin-1tauopathies

Substanzen

BiomarkersNerve Tissue ProteinsSCRN1 protein, humantau Proteins

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Neurology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

Förderung

  • NIH HHS
  • Alzheimer's Association
  • Vetenskapsrådet
  • Alzheimerfonden

Zitieren

APA

Weiner, S., Sauer, M., Brinkmalm, G., Constantinescu, J., Constantinescu, R., Gomes, B. F., Becker, B., Nellgård, B., Dalla, K., Galasko, D., Zetterberg, H., Blennow, K., & Gobom, J. (2023). SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13042

Vancouver

Weiner S, Sauer M, Brinkmalm G, Constantinescu J, Constantinescu R, Gomes BF, et al. SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease. Alzheimer's & Dementia. 2023. doi:10.1002/alz.13042

BibTeX
@article{Weiner2023,
  author = {Weiner, Sophia and Sauer, Mathias and Brinkmalm, Gunnar and Constantinescu, Julius and Constantinescu, Radu and Gomes, Bárbara Fernandes and Becker, Bruno and Nellgård, Bengt and Dalla, Keti and Galasko, Douglas and Zetterberg, Henrik and Blennow, Kaj and Gobom, Johan},
  title = {SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  doi = {10.1002/alz.13042}
}
Kostenlos starten →